Patents Examined by Niloofar Rahmani
  • Heterocyclic compounds as BET inhibitors
    Patent number: 11584756
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 21, 2023
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • Cannabinoid receptor type 2 (CB2) modulators and uses thereof
    Patent number: 11564928
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 31, 2023
    Assignee: Teon Therapeutics, Inc.
    Inventors: Elfatih Elzein, Jiwen Liu
  • Compounds and uses thereof
    Patent number: 11560381
    Abstract: The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: January 24, 2023
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Sabine K. Ruppel, Zhaoxia Yang, Jason T. Lowe, Johannes H. Voigt, Matthew Netherton
  • Substituted naphthalene diimides and their use
    Patent number: 11560380
    Abstract: The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers. The NDIs are a compound of Formula I.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: January 24, 2023
    Assignee: UCL Business Ltd
    Inventors: Stephen Neidle, Richard Angell, Sally Oxenford
  • Treatment of osteoarthritis
    Patent number: 11560378
    Abstract: Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 24, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 11560377
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: January 24, 2023
    Assignee: Guris, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 11547701
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 10, 2023
    Assignees: Valo Health, Inc., Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Transglutaminase 2 (TG2) inhibitors
    Patent number: 11548892
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: January 10, 2023
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Thomas R. Diraimondo, Sergio G. Duron
  • HPK1 antagonists and uses thereof
    Patent number: 11548890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 10, 2023
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 11548887
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: January 10, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • Dihydropyrrolopyridine inhibitors of ROR-gamma
    Patent number: 11535614
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 27, 2022
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
  • Antitubercular compounds
    Patent number: 11530217
    Abstract: Anti-tubercular compounds include trisubstituted indolizines having the following structural formula: wherein R1 is selected from the group consisting of 4-OCH3, 4-Cl, 4-Br, 4-F, 2-NO2, 3,5-CF3, CN, CH3, R2 is COOCH3, COOC2H5, and R3 is H and COOCH3.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: December 20, 2022
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Mohamed A. Morsy, Sandeep Chandrashekharappa, Melendran Pillay, Pran Kishore Deb
  • Small molecule inhibition of transcription factor SALL4 and uses thereof
    Patent number: 11530209
    Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 20, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jun Qi, Anthony Varca, Li Chai
  • YAP1 inhibitors that target the interaction of YAP1 with Oct4
    Patent number: 11530182
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WW domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit sternness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: December 20, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • Large scale purification of castanospermine
    Patent number: 11518762
    Abstract: The invention concerns a scalable, large-scale castanospermine preparation method that yields levels of purity greater than 98% from castanospermine-containing plant sources, such as Castanospermum australe seed material.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: December 6, 2022
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Eric Holmes, Gary Ostrander
  • Tricyclic compound, preparation method therefor and use thereof
    Patent number: 11518766
    Abstract: A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.
    Type: Grant
    Filed: June 28, 2020
    Date of Patent: December 6, 2022
    Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD., JIANGXI JEMINCARE GROUP CO., LTD.
    Inventors: Shuchun Guo, Jiangwei Wang, Shan Yao, Yong Zhang, Zhangping Kang, Qiong Zhang, Yan Ye, Jianbiao Peng, Haibing Guo
  • Macrocycle and composition comprising thereof
    Patent number: 11517561
    Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: December 6, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Preparation method for epoxy compound having alkoxysilyl group
    Patent number: 11512100
    Abstract: Provided is a method for preparing an epoxy compound having an alkoxysilyl group effectively by using a mild catalyst as well as an aromatic alcohol ring-opening agent. The preparation method for an epoxy compound having an alkoxysilyl group includes: performing a ring opening step by reacting an epoxy compound having an epoxide group, which is a starting material, with an aromatic alcohol ring-opening agent in the presence of a phosphine-based catalyst and an optional solvent so as to obtain an intermediate having a partially ring-opened epoxide group; and performing an alkoxysilylation step by reacting the intermediate having a partially ring-opened epoxide with isocyanate alkoxysilane.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: November 29, 2022
    Assignee: KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY
    Inventors: Yun Ju Kim, Hyun Aee Chun, Su Jin Park, Sook Yeon Park
  • Azaindolylpyridone and diazaindolylpyridone compounds
    Patent number: 11498919
    Abstract: The invention provides novel azaindolylpyridone and diazaindolylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory diseases, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R2, R3 and X are as defined in the specification.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 15, 2022
    Assignee: Sprint Bioscience AB
    Inventors: Johan Lindström, Rickard Forsblom, Fredrik Rahm, Jenny Viklund
  • 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
    Patent number: 11498920
    Abstract: Novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds that are useful in the treatment of lymphomas, leukaemias, and solid tumors.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 15, 2022
    Assignee: MASARYKOVA UNIVERZITA
    Inventors: Vitezslav Bryja, Pavlina Janovska, Michaela Gregorova, Vaclav Nemec, Prashant Khirsariya, Kamil Paruch